Results 211 to 220 of about 30,927 (236)
Ibrutinib promising in subtype of DLBCL [PDF]
The Lancet Oncology, 2015 Patients with the activated B-celllike (ABC) subtype of diff use large B-cell lymphoma were more likely to respond to ibrutinib than were those with the germinal centre B-celllike (GCB) subtype of the disease, according to results of a phase 2 study.
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Ibrutinib: First Global Approval
Drugs, 2014Ibrutinib (Imbruvica™) is a small molecule, first-in-class, once-daily, orally available, Bruton's tyrosine kinase inhibitor that is under development for the treatment of B cell malignancies, including chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and diffuse large B cell lymphoma (DLBCL), as well as multiple myeloma (MM), follicular
Mark Sanford, Fiona Cameron
openaire +2 more sources
New Approved Indication for Ibrutinib
AJN, American Journal of Nursing, 2014* Ibrutinib (Imbruvica) has been approved to treat chronic lymphocytic leukemia in patients who've received treatment at least once with other drug therapy. * Common adverse effects are numerous and include thrombocytopenia, diarrhea, bruising, neutropenia, anemia, upper respiratory tract infection, fatigue, musculoskeletal pain, rash, fever ...
openaire +3 more sources
Ibrutinib in B lymphoid malignancies
Expert Opinion on Pharmacotherapy, 2015Most lymphomas and lymphoid leukemias are of B cell origin. Indolent B cell lymphomas, most commonly follicular lymphoma but including Waldenstrom's macroglobulinemia and mantle cell lymphoma, as well as chronic lymphocytic leukemia, are incurable with standard therapy. New treatments are needed.
openaire +3 more sources
Overcoming ibrutinib resistance
Science-Business eXchange, 2014The CDK4 inhibitor palbociclib might help overcome ibrutinib resistance in mantle cell lymphoma by restoring sensitivity to inhibitors of BTK or PI3K.
openaire +2 more sources
Ibrutinib for Chronic Lymphocytic Leukemia
New England Journal of Medicine, 2016Antonio Cuneo +2 more
openaire +6 more sources
Fluconazole Increases Ibrutinib Concentration
American Journal of Therapeutics, 2020Toyotaka Kawamata +3 more
openaire +3 more sources
Ibrutinib: searching for a partner drug
The Lancet Oncology, 2019Arnon P. Kater, Jennifer R. Brown
openaire +3 more sources